PSPro Maps Spatial Proteomes at Cell-Type Resolution

Spatial proteomics must solve two problems at once: identifying many proteins and assigning them to the correct cellular context. The 2025 study by Mao and colleagues addresses this tension with proximity labeling for spatial proteomics, or PSPro. Rather than relying exclusively on physical isolation of tissue regions or imaging of a predefined antibody panel, PSPro uses antibody-guided labeling to capture broader proteome information from selected cell types in situ.

Study Background and Research Question

Complex tissues contain multiple interacting cell populations whose molecular states depend on both identity and location. A tumor slice, for example, may include malignant cells, immune subsets, stromal cells, and vascular components arranged in spatially heterogeneous niches. Measuring proteins without preserving this organization can obscure local biology, while maintaining spatial information often reduces proteome depth or throughput.

As summarized in the reference study by Mao et al., laser microdissection-mass spectrometry can connect proteomic measurements to anatomical regions but may become slow and operationally complex when sampling increasingly small areas. Antibody-based imaging provides precise localization, yet it is generally constrained by the number of markers that can be measured and by the need to select targets in advance. The central research question was therefore whether antibody-targeted proximity labeling could combine cell-type specificity, spatial retention, and deeper proteome coverage in a single tissue section.

Key Innovation from the Reference Study

PSPro changes the analytical role of an antibody. In conventional immunostaining, an antibody primarily identifies one epitope and produces a localized image. In the PSPro framework, the antibody acts as a spatial address: once directed toward a cell-type-associated marker, it enables local labeling of nearby biomolecular targets. Those labeled molecules can then be affinity-purified and analyzed by proteomics. The conceptual shift is from an antibody-epitope measurement to an antibody-cell-type proteome measurement.

The all-at-once design is especially important. Instead of repeatedly cutting separate regions for every cell population, the workflow is intended to enrich proteomes associated with multiple cell types from the same tissue slice. The authors also integrated laser microdissection with PSPro, allowing spatially separated regions within a tumor to be compared while retaining the same general labeling and enrichment logic. This combination makes PSPro complementary to, rather than simply a replacement for, LMD-based spatial proteomics.

According to the published article, the innovation depends on two coordinated optimizations: the selectivity and coverage of antibody-targeted proximity labeling, and the efficiency of affinity purification. Both are necessary. Highly localized labeling is not useful if nonspecific background dominates, while efficient capture is not sufficient if the labeling radius or antibody targeting is poorly controlled.

Methods and Experimental Design Insights

The experimental workflow began with tissue slices and cell-type-defining antibodies. The authors optimized labeling parameters to improve the balance between local signal, selectivity, and the number of proteins recovered. After labeling, affinity purification was used to enrich the modified material before proteomic identification. This design avoids requiring every protein of interest to have a dedicated imaging antibody, because the antibody establishes the location and the labeling reaction samples nearby proteins.

The study evaluated PSPro in pancreatic tumor and spleen tissue, providing biologically different test environments. The authors benchmarked its performance against flow cytometry-based and LMD-based proteomic workflows. These comparisons are useful because they assess more than raw protein counts: they test whether expected cell-type markers are recovered and whether the resulting profiles are sufficiently selective to distinguish tissue populations.

For spatial heterogeneity analysis, the authors added LMD to the PSPro workflow. Regions from the same pancreatic tumor slice could therefore be separated according to their anatomical position and compared at the proteome level. This is a meaningful design choice because tissue-to-tissue variation can otherwise confound regional comparisons. The resulting workflow links a molecular profile to both a cell-type marker and a sampled location.

Protocol Parameters

• Tissue context: The reported applications used pancreatic tumor and spleen slices; adapting PSPro to another tissue should begin with an assessment of fixation, morphology, and antigen accessibility.
• Cell-type targeting: Use antibodies against validated markers whose distribution is known in the tissue. Marker specificity is a practical determinant of the resulting proteome assignment.
• Labeling conditions: The study emphasizes fine-tuned labeling parameters rather than a universal setting. New antibody, tissue, or fixation combinations should therefore be re-optimized instead of transferred unchanged.
• Proteome capture: Affinity purification follows local labeling and is central to recovering sufficient material for downstream proteomic analysis.
• Spatial comparison: Add laser microdissection when the question concerns regional variation within one tissue slice rather than only broad cell-type differences.

These parameters separate what the paper directly demonstrates from practical implementation advice. The study supports the overall sequence of targeted labeling, affinity enrichment, and proteomic analysis; exact reagent concentrations, incubation times, and instrument settings should be taken from the full methods and validated in the user’s own tissue system.

Core Findings and Why They Matter

PSPro enriched thousands of proteins associated with known markers across ten cell types in tumor and spleen slices, as reported in the Cell Systems paper. The significance is not simply the size of the protein list. Recovery of expected markers indicates that the labeling and purification strategy retained cell-type information while expanding beyond a small set of directly imaged epitopes.

The study also showed that PSPro could reveal proteomic differences between spatially distinct cancer-cell and immune-cell subpopulations in pancreatic tumor tissue. Such differences may be missed when all cells from a tumor are pooled or when a region is defined only by morphology. Spatially resolved proteomes can help distinguish a cell population’s baseline identity from changes associated with its local microenvironment.

The benchmarking experiments further position PSPro as a middle-ground strategy. Flow cytometry can provide strong cell-type separation but usually requires tissue dissociation, which removes spatial coordinates. LMD preserves coordinates but can impose a sampling and throughput burden. PSPro retains tissue architecture during labeling and can be combined with LMD when finer regional subdivision is needed. Its practical value is therefore greatest in questions that require both proteome breadth and spatially anchored cell-type information.

Comparison with Existing Internal Articles

The internal article Biotin-XX Tyramide Reagent: Precision Cell Surface Labeling focuses on membrane-impermeant labeling chemistry and signal localization. That perspective is useful for understanding how probe permeability and labeling radius can influence extracellular or surface-associated measurements, whereas the reference paper focuses on the complete cell-type proteome workflow and its tissue-level performance.

A second resource, Biotin-XX Tyramide Reagent: Benchmark for Membrane-Impair..., emphasizes proximity labeling applications in immunohistochemistry and in situ hybridization. It provides a chemistry-oriented complement to PSPro, but it should not be treated as independent validation of the paper’s results. The study’s evidence concerns PSPro as a workflow; any specific commercial probe or assay format requires separate optimization.

Limitations and Transferability

PSPro remains dependent on antibody performance. A marker that is expressed by several cell types, poorly preserved during fixation, or sterically inaccessible can reduce assignment accuracy before the proteomic stage begins. Cell-type labels should therefore be interpreted as antibody-defined capture classes, not automatically as perfect biological cell identities.

Proximity labeling also measures a chemically defined neighborhood rather than an unbiased inventory of every protein in a cell. Enrichment favors targets that are accessible within the effective labeling range and compatible with the capture chemistry. Consequently, a protein’s absence from a PSPro dataset does not necessarily indicate biological absence, and relative signal should not be interpreted as a direct concentration measurement without appropriate controls.

The reported performance in pancreatic tumor and spleen slices demonstrates feasibility across two tissue contexts, but transferability to other organs, fixation regimes, disease models, or highly rare cell populations is not guaranteed. Antibody panels, tissue thickness, labeling selectivity, background chemistry, and mass-spectrometric depth may all require adjustment. Likewise, the sub-micrometer spatial capability described by the authors should not be conflated with physically isolating and sequencing every individual cell. PSPro provides spatially anchored molecular enrichment; the effective biological resolution depends on labeling geometry, marker distribution, tissue structure, and the downstream sampling design.

Finally, comparisons with flow cytometry and LMD-based proteomics should be read as workflow benchmarking rather than a universal ranking. Each method answers a different version of the spatial biology problem. PSPro is most compelling when researchers need broad protein coverage from marker-defined populations and want to preserve the option of comparing regions within the same tissue section.

Research Support Resources

For researchers adapting antibody-guided labeling or related tissue-detection workflows, Biotin-XX Tyramide Reagent (SKU A8012) is a membrane-impermeant biotinylated tyramide probe. It is also described in some workflow contexts as biotin-LC-LC-tyramide and can support tyramide signal amplification, immunohistochemistry signal amplification, in situ hybridization signal amplification, and cell surface protein labeling when the chemistry is compatible with the experimental design. The product information describes HRP-dependent localized deposition; researchers should validate labeling selectivity, tissue compatibility, and capture performance rather than assume equivalence to the exact PSPro conditions.